Evaluation of Whole-body CZT Camera in Gated Tomographic Radionuclide Angiography

Centre Hospitalier Régional d'Orléans73 enrolled

Overview

Tomographic radionuclide angiography (or blood pool) is a reproducible method to evaluate left ventricular ejection fraction that is needed during oncological treatments or to evaluate cardiopathies. Cardiac-dedicated CZT systems allowed dose or time reduction. Multipurpose CZT cameras have not yet been evaluated in this indication. Moreover, the impact of attenuation correction is not known.

Tomographic radionuclide angiography is a simple, rapid and reproducible method of cardiac function measurement, including left (LVEF) and right (RVEF) ventricular ejection fractions. In addition to cardiological indications, this examination is often performed as part of cardiac toxicity screening during the various oncological treatments. This indication is all the more true since the arrival of CZT gamma cameras dedicated to cardiological studies has made it possible to reduce injected activities, as well as examination times. The multipurpose CZT camera allows tomoscintigraphic acquisitions to be carried out using CZT technology as well. Unlike the CZT gamma cameras dedicated to cardiological studies, this system can be used for the exploration of different organs, and also allows the realization of CT slices for attenuation correction. Patients included in this study will be double scanned both on a dedicated cardiac CZT camera and on multipurpose CZT camera, with CT. LVEF and RVEF will be then compared.

Study Type

INTERVENTIONAL

Allocation

Purpose

OTHER

Masking

NONE

Enrollment

Conditions

Cardiac Function

Interventions

SPECT acquisitionsOTHER

All patients will undergo SPECT acquisitions with both multipurpose CZT camera and cardiac dedicated CZT camera.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients referred to our Nuclear Medicine department for evaluation of cardiac function. Exclusion Criteria: * Patients treated with chemotherapy within 12 days. * Under 18 years old patients. * Pregnant women or at risk of pregnancy. * Breast feeding. * Painful patients. * Patients under guardianship. * Patients in whom a standard examination is not feasible (agitation). * Patients who do not benefit from a social security system

Locations (1)

CHR d'Orleans

Orléans, France

Outcomes

Primary Outcomes

Assessment of left and right ventricular volumes and ejection fraction.

Automatic quantification of left and right ventricular volumes, left ventricle ejection fraction (LVEF) and right ventricle ejection fraction (RVEF) using BPGs software (Cedars-Sinai Medical Center, Los Angeles, USA).

Time frame: Day 0

Secondary Outcomes

Assessment of left and ventricular volumes and ejection fraction with attenuation correction.

Assessment of an attenuation map from low dose CT data. Automatic quantification of left and right ventricular volumes, LVEF and RVEF using BPGs software (Cedars-Sinai Medical Center, Los Angeles, USA).

Time frame: Day 0

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.